Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension

Main Article Content

Diamant Thaçi
Ron Vender
Menno de Rie
Curdin Conrad
Jennifer Soung
Bruce Strober
Maggie Wang
Nancy Cross
Delphine Deherder
Natalie Nunez Gomez
Alice B Gottlieb

Keywords

bimekizumab, psoriasis, moderate to severe, clinical trial, BE RIGHT, efficacy, safety

Abstract

N/A

References

1. Thaçi D et al. Presented at EADV 2021, P1324

2. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

3. BE BRIGHT: clinicaltrials.gov/ct2/show/NCT03598790.

Most read articles by the same author(s)

1 2 3 4 5 > >>